Optimization of Deprescribing Antidepressants in Nursing Home Residents With Dementia
Launched by UNIVERSITY OF COPENHAGEN · Jul 30, 2021
Trial Information
Current as of July 06, 2025
Completed
Keywords
ClinConnect Summary
It is estimated that more than 87.000 in Denmark are living with dementia, with more than 8000 new cases each year. The majority of older persons with dementia are living at home but in a minority problems with daily activities necessitates relocation to a nursing home. Besides cognitive impairment, up to 90 % of the institutionalized older people with dementia may experience behavioral and psychological symptoms of dementia (BPSD) such as anxiety, agitation, hallucinations, depression, and apathy. An overuse of antidepressants is reported and in Denmark, about half of all nursing home resi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥72 years old
- • Either have a diagnosis of dementia or have a severe cognitive impairment as judged by the GP
- • Are permanently living at the nursing home
- • Are prescribed at least one antidepressant with the following ATC-codes
- • Selective serotonin reuptake inhibitors (SSRIs): N06AB10 (Escitalopram); N06AB04 (Citalopram); N06AB08 (Fluvoxamin); N06AB03 (Fluoxetin); N06AB05 (Paroxetin); N06AB06 (Sertralin);
- • Serotonin-Norepinephrine Reuptake inhibitors (SNRIs): N06AX21 (Duloxetin); N06AX16 (Venlafaxin);
- • Tricyclic antidepressants (TCAs): N06AA09 (Amitriptylin); N06AA04 (Clomipramin); N06AA02 (Imipramin); N06AA10 (Nortriptylin); (Dosulepin); N06AA17
- • Noradrenergic and specific serotonergic antidepressants (NaSSAs) / Atypical antidepressants N06AX03 (Mianserin); N06AX11 (Mirtazapin);
- • Monoamine oxidase inhibitors (MAOIs):N06AF01 (Isocarboxazid);
- • Noradrenaline reuptake inhibitor (NARI): N06AX18 (Reboxetin);
- • Other antidepressant with effect on the serotonin-system: N06AX26 (Vortioxetin);
- • Melatonin agonists: N06AX22 (Agomelatin);
- Exclusion Criteria:
- • They are under treatment of a psychiatrist.
- • They are enrolled in another psychopharmacological trial
- • There is a suspicion of a current clinical, major depression or suicidal behavior and intentions.
- • Receiving end-of-life care
About University Of Copenhagen
The University of Copenhagen, a leading research institution in Denmark, is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including health sciences, pharmacology, and biotechnology, to design and conduct rigorous clinical studies. Committed to ethical standards and scientific integrity, the University of Copenhagen aims to contribute significantly to the global medical community by facilitating groundbreaking research that addresses pressing healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Maarten Pieter Rozing, MD, Ph.D.
Principal Investigator
University of Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials